Combined Radiofrequency Ablation and Double Anti-Angiogenic Protein Therapy to Increase Coagulation Efficacy: An Experimental Study in a Murine Renal Carcinoma Model

Hong Young Jun, PhD¹, Jong-Hyun Ryu, PhD¹, Seung Jae Byun, MD², Chang Won Jeong, PhD¹, Tae-Hoon Kim, PhD¹, Young Hwan Lee, MD, PhD³, Kwon-Ha Yoon, MD, PhD¹, ³

¹Imaging Science Research Center, Departments of ²Surgery and ³Radiology, Wonkwang University School of Medicine, Iksan 570-711, Korea

Objective: To evaluate whether suppression of tumor microvasculature by double anti-angiogenic protein (DAAP) treatment could increase the extent of radiofrequency ablation (RFA)-induced coagulation in a murine renal cell carcinoma model.

Materials and Methods: Renal cell carcinoma cell lines were implanted subcutaneously into 10 nude mice. Four mice received adenoviral DAAP treatment and 6 mice received sterile 0.9% saline solution as DAAP-untreated group. The effect of DAAP was evaluated according to the vascularity by contrast-enhanced ultrasound (CEUS) using microbubbles. Four DAAP-treated mice and 4 DAAP-untreated mice were then treated with RFA, resulting in 3 groups: no-therapy (n = 2), RFA only (n = 4), and RFA combined with DAAP treatment (n = 4). Immediately after RFA, the size of coagulation necrosis and mitochondrial enzyme activity were compared between the groups using analysis of variance (ANOVA) and post hoc test.

Results: The contrast enhancement ratio for tumor vascularization on CEUS was significantly lower in the DAAP treated group than in DAAP-untreated group (30.2 ± 9.9% vs. 77.4 ± 17.3%; p = 0.021). After RFA, the mean coagulation diameter was 0 mm for no-therapy group, 6.7 ± 0.7 mm for the RFA only group and 8.5 ± 0.4 mm for the RFA with DAAP group (ANOVA, p < 0.001). The area of viable mitochondria within the tumor was 27.9 ± 3.9% in no-therapy group, 10.3 ± 4.5% in the RFA only group, and 2.1 ± 0.7% in the RFA with DAAP group (ANOVA, p < 0.001).

Conclusion: Our results suggest the potential value of combining RFA with anti-angiogenic therapy.

Index terms: Radiofrequency ablation; Angiogenesis; Anti-angiogenic protein; Renal cell carcinoma; Mice model

INTRODUCTION

Renal cell carcinoma (RCC) was diagnosed in more than 88400 patients in Europe in 2008 and caused about 39300 deaths (1, 2). Many cases are incidentally found during cross-sectional imaging examinations such as ultrasonography (3, 4). Further, there have been major advances in relatively less invasive treatments for RCC, as compared to that in nephrectomy (5, 6). These developments include laparoscopic nephrectomy, and ablation therapies such as cryoablation and percutaneous image-guided radiofrequency ablation (RFA) (7-9).

Recently, RFA was reported to be safer for patients than radical nephrectomy. As a result, RFA has been performed increasingly to treat small tumors, as it provides effective destruction of RCC stage T1a tumors (< 4 cm) (10, 11). However, the major limitation of RFA is incomplete treatment of larger lesions such as RCC stage T1b (> 4 cm).

Several techniques for increasing tumor destruction to aid in RFA have included surgical and angiographic techniques, such as the Pringle maneuver (i.e., vascular clamping of
RF Ablation in Combination with DAAP Therapy

portal inflow at surgery) and chemoembolization (12, 13). However, these techniques are disadvantageous since they require invasive procedures, contrary to the purported benefit of minimally invasive therapy. Thus, concomitant administration of adjuvant antivascular pharmaceutical agents such as double anti-angiogenic protein (DAAP) agents that maximize the antivascular effect would be of considerable clinical interest (14, 15). DAAP, which can bind and block both VEGF-A and angiopoietins, is more highly effective than VEGF-Trap alone in inducing tumor vessel regression and reducing subsequent blood flow in the established tumor (16).

Furthermore, the double blockade of VEGF-A and Ang-2 with DAAP showed marked effectiveness in suppressing tumor angiogenesis and metastasis of implanted and spontaneous solid tumors and in reducing ascites formation and vascular leakage in advanced ovarian cancer (14). Accordingly, we hypothesized that combining RFA with double anti-angiogenic therapy has increased ablation efficacy. The purpose of this study was to evaluate whether suppression of tumor microvasculature by DAAP treatment could increase the extent of RF-induced coagulation in a murine RCC model.

MATERIALS AND METHODS

Experimental Animals and Generation of Tumor Model

Specific pathogen-free nude mice were purchased from Central Laboratory Animal Inc. (Seoul, Korea), and were bred in our pathogen-free animal facility. Ten male nude mice (aged 5 weeks and weighing 20 g each) were used for this study. All mice lived in a system equipped with day-night light cycling and were provided with standard mouse chow. Experimental procedures were performed with approval from the Animal Care Committee of our institute.

Renal cell carcinoma 786-O human renal cell carcinoma cells (5 x 10⁷) suspended in 0.1-mL phosphate-buffered saline were injected subcutaneously into the unilateral inguinal area of nude mice and were allowed to expand for 14 days until the tumors grew to a size of approximately 1.0 cm³.

Treatment with DAAP

A recombinant adenoviral vector encoding the DAAP gene was provided by Koh et al. (14). For DAAP treatment, the indicated amount (1 x 10⁹ plaque forming units [pfu]) of diluted adenovirus in 50 µL of sterile 0.9% saline was injected intravenously through the tail vein approximately 14 days (tumors 1.5–2.0 cm in diameter) after implanting RCC-786-O in 4 nude mice (DAAP-treated group). At the same time, 6 mice were injected in the tail vein with 50 µL of sterile 0.9% saline (DAAP-untreated group).

Contrast-Enhanced Ultrasound Imaging

Microbubbles used for contrast-enhanced ultrasound (CEUS) were prepared according to our previously described method (17). Briefly, microbubble materials (DSPC, PEG 40 stearate, and DSPE-PEG2000-biotin) were weighed as dry solids and combined, followed by chloroform addition dropwise to the dry surfactant mixture until both components were completely dissolved. The solution was placed under a fume hood to allow evaporation until only a dry white film was left on the inside of the vial. Residual chloroform was then removed by placing the uncapped vial in a desiccator for 3 minutes. The film was hydrated with phosphate-buffered saline, an aqueous solution consisting of 121.5 mmol/L NaCl, 25.2 mmol/L Na₂HPO₄, and 4.8 mmol/L KH₂PO₄. After the addition of phosphate-buffered saline to the dried film with the phospholipid component, the vial was tightly capped and incubated at 62ºC for a period of 2 to 4 hours to fully hydrate the coating materials.

Previous studies have shown strong correlations between histologic microvascular density and intensity of CEUS in the mouse tumor model (18-20). The modulation of RCC tumor microvasculature was evaluated and compared by CEUS as in previous studies. The CEUS evaluation was performed immediately before RF ablation with or without DAAP treatment in all mice.

To assess the contrast enhancement of the microbubbles, we used clinical ultrasound equipment (Vivid 7, GE Vingmed Ultrasound, Horten, Norway) in the grayscale pulse inversion mode. Ultrasound images were acquired with a broadband L9 transducer and a low mechanical index of 0.07. The images were recorded digitally and analyzed offline, and the video intensity within the tumor was measured using the ImageJ software (National Institutes of Health, Bethesda, MD, USA). The mice were placed in an induction chamber with 4% isoflurane in oxygen to induce anesthesia. During imaging, anesthesia of mice was maintained with 1.5% isoflurane in oxygen, and the mice were allowed to recover between image acquisitions. Ultrasound images of the tumor tissue were acquired at 1 minute after bolus intravenous injection of microbubbles. Each mouse was given a bolus injection of 1 x 10⁶/g of microbubbles in 0.05
mL saline via the tail vein.

To assess the micro-vascular enhancement achieved with the contrast agent, the video intensity of the tumor tissue was determined and the contrast enhancement ratios (CER) were calculated in the regions of interest of the whole tumor volume by measuring both before and after microbubbles injection relative to the whole tumor volume. Quantitative analysis of each region of interest was used to extract the mean value of signal enhancement at each time point, and the CER were then calculated in each tumor tissue. The CER at the tumor tissue between precontrast (C0) and postcontrast (C1) images was calculated using the following equation: \( \text{CER} = \frac{C1 - C0}{C0} \).

**RFA**

Four mice treated with DAAP and 4 of the 6 mice in the DAAP-untreated group were subsequently treated with RFA 7 days after DAAP or sterile saline injection. The remaining 2 DAAP-untreated mice did not receive RFA therapy. As a result, this study included 3 groups: no-therapy (i.e., sterile saline injection only; \( n = 2 \)), RFA only (i.e., RFA following sterile saline injection; \( n = 4 \)), and RFA combined with DAAP treatment (i.e., RFA following DAAP injection; \( n = 4 \)). A 500-kHz RF generator (CC-1; Valley-Lab, Boulder, CO, USA) was used to apply conventional monopolar RF energy. This generator was selected because it is available for clinical use and is capable of monitoring impedance, tip temperature, and other parameters of the ablation. RF energy was applied for 5 minutes into the tumor, with the generator output titrated to maintain a designated tip temperature: a mean temperature of 70 ± 2°C for each tumor. RF tip was performed using cool-tip type electrodes with a 1-cm active tip. RFA was performed as previously described by Horkan et al. (21) and Hines-Peralta et al. (22).

**Measurement of RF Ablation Effect**

All mice were euthanized immediately after RFA with 4% isoflurane in oxygen. After the entire tumor was removed and embedded in agar, 3 slices were prepared using a vibratome. The area of coagulation necrosis was measured by virtual caliper and assessed mitochondrial enzyme activity after incubation of the tumor samples in a 2% solution of 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) at 37°C for 30 minutes. The absence of mitochondrial enzyme activity accurately reflects irreversible cellular injury induced by percutaneous tumor ablation (23). With this assessment method of TTC staining, viable area with intact mitochondrial enzyme activity is stained red, while ablated area does not have a red color. The viable area of the tumor area was then calculated as a percentage of the viable area in the total area of the tumor and overlaid as a red color display on the photograph image using the image analysis tool (Matlab 7.4, Mathworks Inc., USA).

**Statistical Analysis**

Modulation analysis of RCC tumor microvasculature was performed using the nonparametric Mann-Whitney U test. The TTC staining analysis for mitochondrial dehydrogenase activity was assessed with one-way analysis of variance (ANOVA) and post hoc Tukey’s test. Data were presented as mean ± standard deviation. Statistical significance was set at \( p < 0.05 \). All statistical analysis was performed using SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA).

**RESULTS**

**Tumor Measurement by Contrast-Enhanced Ultrasound Imaging**

The mean tumor area measured at the largest cross-section by ultrasound before RFA was 77.1 ± 20.2 mm² and 69.5 ± 28.3 mm² in DAAP-untreated group and DAAP-treated group, respectively, at 7 days after administration DAAP, with no significant difference between groups (Table 1). CEUS images captured at 1 minute after intravenous injection of microbubbles showed lower signal intensity in DAAP-treated mice than in DAAP-untreated mice (Fig. 1). The CER for tumor vascularization on CEUS images were significantly lower in DAAP-treated group (30.2 ± 9.9%) than in DAAP-untreated group (77.4 ± 17.3%; \( p = 0.021 \)) (Fig. 2).

**Effect of DAAP on RF-Induced Tumor Coagulation**

Figure 3 showed TTC staining in the 3 groups for...
RF Ablation in Combination with DAAP Therapy

assessment of the efficacy of RFA only and RFA combined with DAAP treatment. The mean coagulation diameter (white area) measured 8.5 ± 0.4 mm in RFA combined with DAAP group, 6.7 ± 0.7 mm in RFA only group, and 0 mm in no-therapy group (ANOVA, \( p < 0.001 \)) (Table 2). Using Matlab analysis, the area of viable mitochondria showed significant difference between the 3 groups (ANOVA, \( p < 0.001 \)). Figure 4 demonstrated the area of viable mitochondria within the tumor and its averaged values were summarized in Table 2. The area of viable mitochondria within the tumor was significantly smaller in RFA combined with DAAP group, as compared with RFA only group (red area, 2.1 ± 0.7% vs. 10.3 ± 4.5%; \( p = 0.024 \)) and in RFA only group, as compared with no-therapy group (red area, 10.3 ± 4.5% vs. 27.9 ± 3.9%; \( p = 0.001 \)).

Fig. 1. Comparison of contrast-enhanced ultrasound images of tumors after injection of microbubbles. A, B. Images of untreated tumor show strong enhancement in intratumor area (yellow circle) after injection of microbubbles. C, D. In contrast, treated tumor with double anti-angiogenic protein (DAAP) shows similar contrast enhancement after injection of microbubbles.

Fig. 2. Graph demonstrating contrast enhancement ratios (CER). CER after injection of microbubbles was significantly different between untreated tumor and double anti-angiogenic protein (DAAP)-treated tumor. \(* p < 0.05\).
DISCUSSION

Our results suggested that pretreatment of RCC tumors with the antiangiogenic agent DAAP in nude mice can decrease tumor vascularity and substantially enhance coagulation when given in conjunction with RFA. This interaction is likely mediated by the well-documented antiangiogenic properties of DAAP. DAAP appears to distribute well in the tumor environment and block VEGF-A and Ang-2 in a synergistic manner, possibly via increasing ligand aggregation because of increased avidity. DAAP has relatively high bioavailability and a longer half-life than either VEGF-Trap or Tie2-Fc. In addition, DAAP is effective in inducing tumor vessel regression and reducing subsequent blood flow in established tumors (14). The authors suggested that DAAP can be an effective therapeutic strategy for blocking tumor angiogenesis, metastasis, and vascular leakage. Regarding the toxicity, they reported that repeated DAAP treatment induced anticipated toxicities such as thrombocytosis, hypertension and microalbuminuria.

Table 2. Effect of DAAP on RF-Induced Tumor Coagulation

|                | No-Therapy (n = 2) | RFA Only (n = 4) | RFA with DAAP (n = 4) | P*  |
|----------------|-------------------|-----------------|-----------------------|-----|
| Coagulation diameter (mm) | 0                 | 6.7 ± 0.7       | 8.5 ± 0.4             | < 0.001† |
| Area of viable mitochondria (%) | 27.9 ± 3.9        | 10.3 ± 4.5      | 2.1 ± 0.7             | < 0.001‡ |

*Statistical analysis was performed with one-way ANOVA, †Post hoc test with Tukey’s test: between ‘no-therapy’ and ‘RFA only’, p < 0.001; between ‘RFA only’ and ‘RFA with DAAP’, p = 0.005; between ‘no-therapy’ and ‘RFA with DAAP’, p < 0.001, ‡Post hoc test with Tukey’s test: between ‘no-therapy’ and ‘RFA only’, p = 0.001; between ‘RFA only’ and ‘RFA with DAAP’, p = 0.024; between ‘no-therapy’ and ‘RFA with DAAP’, p < 0.001. DAAP = double anti-angiogenic protein, RFA = radiofrequency ablation.

Fig. 3. Assessment for mitochondrial viable area. Cross sections of three gross pathologic specimens stained with 2,3,5-triphenyl-2H-tetrazolium chloride. Mitochondrial activity is shown in red. Nonviable ablated tumor remains white (arrows). Mitochondrial activity is clearly seen in (A) untreated tumor but not in treated tumor with (B) radiofrequency ablation (RFA) only or with (C) RFA and double anti-angiogenic protein (DAAP). (D-F) Remaining viable mitochondria were overlaid as red color using MATLAB.
Our study showed that the effect of DAAP could not be evaluated on grayscale ultrasound. On the contrary, the CEUS images demonstrated that the CER for tumor vascularization were significantly lower in the DAAP treatment group, as compared to untreated group. To better understand the effect of DAAP, CEUS is a simple way to noninvasively image tumoral vascularity and detect any reductions in tumoral vascularity after treatment. CEUS is a widely used imaging technique in which microbubbles help to improve contrast between blood vessels and the surrounding tissue during ultrasound imaging. CEUS has been used to assess functional changes in response to antiangiogenic treatment in patients with RCC (23–25). Furthermore, it may enable more accurate prediction of RFA size and more precise determination of antiangiogenic therapy failure before RFA. Direct assessment with CEUS may help to evaluate endpoints in combination therapy clinical trials.

Combination therapy of DAAP and RFA may help to overcome the size limitation. Specifically, reduction of the microvasculature density could cause cure in stage T1b tumors (> 4 cm of RCC) that cannot be treated effectively with RFA only (28). Furthermore, sufficient tumor destruction may be achieved with a reduction in the duration time of RFA therapy (29). Combination therapy could improve uniformity of heat deposition during RFA and potentially reduce treatment failure.

We acknowledge several limitations of our study. First, our analysis was limited by the use of only 1 animal tumor model. Further investigation is needed to determine if the interaction observed here in RCC of nude mice can be generalized to other tumor types. As described above, DAAP has a broad spectrum of activity, but its activity when in combination with RFA may likely depend on the sensitivity of the tumor to antiangiogenic therapy, as well as on tumor size. Second, even though we used CEUS after DAAP therapy, we also measured CEUS at a single site in the tumor. Therefore, the antiangiogenic effects of DAAP in the global tumor remain unclear. For these reasons, a secondary method of vascularity analysis such as computed tomography or magnetic resonance perfusion imaging may enable more precise determination of the sufficiency of antiangiogenic therapy before RFA. Finally, treatment was provided for 9 days on the basis of observed changes in tumor size, but optimal dosing concentration and duration remain unclear and warrant further tumor-specific studies.

In conclusion, our results suggested the potential value of combining RFA with antiangiogenic therapy. However, further investigation is needed, including validation in other tumor types. In addition, combination of DAAP with other antiangiogenic therapies, as well as combinations with other forms of thermal ablation, such as microwave ablation, should be considered. Future studies should also include clinical trials of potentially additive therapies for the treatment of RCC and possibly other tumor types.

REFERENCES

1. Ferlay J, Parkin DM, Stelarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765–781
2. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398–406
3. Kim SY, Woo S, Hwang SJ, Moon MH, Sung CK, Lee HJ, et al. Usefulness of resistive index on spectral Doppler ultrasonography in the detection of renal cell carcinoma in patients with end-stage renal disease. Ultrasonography 2014;33:136–142
4. Tranquart F, Correas JM, Martegani A, Greppi B, Bokor D. Feasibility of real time contrast enhanced ultrasound in renal disease. J Radiol 2004;85:31–36
5. Choueiri TK, Schutz FA, Hevelone ND, Nguyen PL, Lipsitz SR, Williams SB, et al. Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results
6. Takahi H, Yamakado K, Soga N, Arima K, Nakatsuaka A, Kashima M, et al. Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma. *Jpn J Radiol* 2010;28:460-468.

7. Gervais DA. Cryoablation versus radiofrequency ablation for renal tumor ablation: time to reassess? *J Vasc Interv Radiol* 2013;24:1135-1138.

8. Raman JD, Hall DW, Caddeu JA. Renal ablative therapy: radiofrequency ablation and cryoablation. *J Surg Oncol* 2009;100:639-644.

9. Pirasteh A, Snyder L, Boncher N, Passalacqua M, Rosenblum D, Prologo JD. Cryoablation vs. radiofrequency ablation for small renal masses. *Acad Radiol* 2011;18:97-100.

10. Park S, Anderson JK, Matsumoto ED, Lotan Y, Josephs S, Caddeu JA. Radiofrequency ablation of renal tumors: intermediate-term results. *J Endourol* 2006;20:569-573.

11. Stern JM, Svatok R, Park S, Hermann M, Lotan Y, Sagolowsky AI, et al. Intermediate comparison of partial nephrectomy and radiofrequency ablation for clinical T1a renal tumours. *BJU Int* 2007;100:287-290.

12. Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. *Cancer* 2002;95:2353-2360.

13. Shen P, Fleming S, Westcott C, Challa V. Laparoscopic radiofrequency ablation of the liver in proximity to major vasculature: effect of the Pringle maneuver. *J Surg Oncol* 2003;83:36-41.

14. Koh YJ, Kim HZ, Hwang SI, Lee JE, Oh N, Jung K, et al. Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. *Cancer Cancer* 2010;18:171-184.

15. Jung K, Lee D, Lim HS, Lee SI, Kim YJ, Lee GM, et al. Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. *J Biol Chem* 2011;286:14410-14418.

16. Ravaud A, Gross-Goupil M, Bellmunt J. Combination therapy in metastatic renal cell cancer. *Semin Oncol* 2013;40:472-481.

17. Jun HY, Park SH, Kim HS, Yoon KH. Long residence time of ultrasound microbubbles targeted to integrin in murine tumor model. *Acad Radiol* 2010;17:54-60.

18. Zhang Q, Yang H, Kang SJ, Wang Y, Wang GD, Coulthard T, et al. In vivo high-frequency, contrast-enhanced ultrasonography of uveal melanoma in mice: imaging features and histopathologic correlations. *Invest Ophthalmol Vis Sci* 2011;52:2662-2668.

19. Hwang M, Hariri G, Lyshchik A, Hallahan DE, Fleischer AC. Correlation of quantified contrast-enhanced sonography with in vivo tumor response. *J Ultrasound Med* 2010;29:597-607.

20. Shiyan L, Pintong H, Zongmin W, Fugang H, Zhiqiang Z, Yan Y, et al. The relationship between enhanced intensity and microvessel density of gastric carcinoma using double contrast-enhanced ultrasonography. *Ultrasound Med Biol* 2009;35:1086-1091.

21. Horkan C, Ahmed M, Liu Z, Gazelle GS, Solazzo SA, Kruskal JB, et al. Radiofrequency ablation: effect of pharmacologic modulation of hepatic and renal blood flow on coagulation diameter in a VX2 tumor model. *J Vasc Interv Radiol* 2004;15:269-274.

22. Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZZ, Goldberg SN. Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. *Radiology* 2006;240:82-89.

23. Wang C, Yu C, Yang F, Yang G. Diagnostic accuracy of contrast-enhanced ultrasound for renal cell carcinoma: a meta-analysis. *Tumour Biol* 2014;35:6343-6350.

24. Siracusano S, Quaia E, Bertolotto M, Ciciliato S, Tiberio A, Belgrano E. The application of ultrasound contrast agents in the characterization of renal tumors. *World J Urol* 2004;22:316-322.

25. Williams R, Hudson JM, Lloyd BA, Sureshkumar AR, Lueck G, Milot L, et al. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy. *Radiology* 2011;260:581-590.

26. Solfati L, Ierace T, Tonolini M, Cova L. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound. *Eur J Radiol* 2004;51 Suppl:S19-S23.

27. Liu JB, Goldberg BB, Merton DA, Rawool NM, Needleman L, Forsberg F. The role of contrast-enhanced sonography for radiofrequency ablation of liver tumors. *J Ultrasound Med* 2003;22:517-523.

28. Hines-Peralta A, Goldberg SN. Review of radiofrequency ablation for renal cell carcinoma. *Clin Cancer Res* 2004;10(18 Pt 2):6328S-6334S.

29. Hakimé A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. *Radiology* 2007;244:464-470.